Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study

American Journal of Ophthalmology

Volumn 169, Issue , 2016, Pages 258-267

  Hoerauf, Hans ^a   Feltgen, Nicolas ^a   Weiss, Claudia ^b   Paulus, Eva Maria ^b   Schmitz Valckenberg, Steffen ^c   Pielen, Amelie ^d   Puri, Pankaj ^e   Berk, Hüsnü ^f   Eter, Nicole ^g   Wiedemann, Peter ^h   Lang, Gabriele E ⁱ   Rehak, Matus ^h,j   Wolf, Armin ^k   Bertelmann, Thomas ^b,l   Hattenbach, Lars Olof ^m  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e ROYAL DERBY HOSPITAL   (United Kingdom)

^f St Elisabeth Hospital   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ UNIVERSITY OF ULM   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY OF MUNICH   (Germany)

^l PHILIPPS UNIVERSITY MARBURG   (Germany)

^m KLINIKUM LUDWIGSHAFEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; DRUG IMPLANT; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CLINICAL EFFECTIVENESS; COLOR FUNDUS PHOTOGRAPHY; CONTROLLED STUDY; DRUG SAFETY; ENDOPHTHALMITIS; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPHEMA; HYPOTHYROIDISM; INTRAOCULAR PRESSURE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA TEAR; SUSTAINED DRUG RELEASE; TRAUMATIC CATARACT; TREATMENT FAILURE; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG IMPLANT; EUROPE; HEALTH STATUS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG IMPLANTS; EUROPE; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; QUALITY OF LIFE; RANIBIZUMAB; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84970005725     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2016.04.020     Document Type: Article

References (24)

1. 1 Shahid, H., Hossain, P., Amoaku, W.M., The management of retinal vein occlusion: is interventional ophthalmology the way forward?. Br J Ophthalmol 90:6 (2006), 627–639.
2. 2 Rogers, S., McIntosh, R.L., Cheung, N., et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:2 (2010), 313–329.e1.
3. 3 Scott, I.U., Management of macular edema associated with retinal vein occlusion. Arch Ophthalmol 130:10 (2012), 1314–1316.
4. 4 Ferrara, N., Damico, L., Shams, N., Lowman, H., Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:4 (2006), 859–870.
5. 5 Brown, D.M., Campochiaro, P.A., Singh, R.P., et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:6 (2010), 1124–1133.e1.
6. 6 Campochiaro, P.A., Brown, D.M., Awh, C.C., et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:10 (2011), 2041–2049.
7. 7 Heier, J.S., Campochiaro, P.A., Yau, L., et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:4 (2012), 802–809.
8. 8 Campochiaro, P.A., Sophie, R., Pearlman, J., et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:1 (2014), 209–219.
9. 9 Haller, J.A., Bandello, F., Belfort, R., et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:6 (2010), 1134–1146.e3.
10. 10 Haller, J.A., Bandello, F., Belfort, R., et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:12 (2011), 2453–2460.
11. 11 Pielen, A., Feltgen, N., Isserstedt, C., Callizo, J., Junker, B., Schmucker, C., Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One, 8(10), 2013, e78538.
12. 12 Kuppermann, B.D., Haller, J.A., Bandello, F., et al. Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:9 (2014), 1743–1749.
13. 13 Coscas, G., Augustin, A., Bandello, F., et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:1 (2014), 1–9.
14. 14 Parravano, M., Oddone, F., Boccassini, B., et al. Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Ophthalmic Res 51:3 (2014), 153–160.
15. 15 Mathew, R., Pearce, E., Muniraju, R., Abdel-Hay, A., Abdul-Hey, A., Sivaprasad, S., Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). Eye (Lond) 28:3 (2014), 318–326.
16. 16 European Medicines Agency, Summary of Product Characteristics. Lucentis 10 mg/ml solution for injection. Novartis, 2013 Available at: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf Accessed September 18, 2014.
17. 17 European Medicines Agency, Summary of Product Characteristics. Ozurdex 700 micrograms intravitreal implant in applicator. Allergan, 2015 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001140/WC500095499.pdf Accessed October 12, 2015.
18. 18 Spaide, R.F., Chang, L.K., Klancnik, J.M., et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:2 (2009), 298–306.
19. 19 Kinge, B., Stordahl, P.B., Forsaa, V., et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 150:3 (2010), 310–314.
20. 20 Gado, A.S., Macky, T.A., Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Experiment Ophthalmol 42:7 (2014), 650–655.
21. 21 Maturi, R.K., Chen, V., Raghinaru, D., et al. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol 8 (2014), 1057–1064.
22. 22 Aref, A.A., Scott, I.U., Oden, N.L., et al. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. JAMA Ophthalmol 133:9 (2015), 1022–1029.
23. 23 Yannuzzi, N.A., Patel, S.N., Bhavsar, K.V., Sugiguchi, F., Freund, K.B., Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol 158:2 (2014), 319–327.e2.
24. 24 COMRADE-Extension. Available at: https://clinicaltrials.gov/ct2/show/NCT01580020. Accessed September 2014.